Ulcerative Colitis
A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Induction Therapy With RO7790121 in Patients With Moderately to Severely Active Ulcerative Colitis.
Study Aim
This study aims to compare the effects of RO7790121 against ‘placebo’. A placebo is a medicine that contains no active ingredients but looks the same as the study medicine. Researchers want to see if RO7790121 works, how well it works and how safe it is.
Eligibility
People aged 18 to 80 years old, with moderately to severely active Ulcerative Colitis. To take part, people also must have taken at least 1 other medicine for UC that didn’t work very well, stopped working or caused unacceptable unwanted effects.
What Is Involved
What Is Involved Participants will be given either RO7790121 OR a placebo, given as a drip into a vein (known as an infusion).
